Introduction
Chronic obstructive pulmonary disease (COPD), a lung illness that advances and results in emphysema, is a significant global health problem. It is often caused by long-term lung inflammation, with tobacco smoke being the main culprit. This case study focuses on Deborah, a 62-year-old female patient with emphysema and an 80-pack-year smoking history.
Deborah’s position is not unique because many COPD sufferers also have comorbid conditions that complicate management. The goal of this case study is to better understand the pathophysiology of COPD, how Deborah’s symptoms relate to it, and how Deborah’s lifestyle and coexisting diseases impact the progression and management of her illness. This in-depth analysis aims to clarify the varied approaches required for effective COPD treatment.
Case Presentation
Deborah, a 62-year-old female patient, presents with tachypnea, dyspnea on exertion, and mild chest discomfort. She was diagnosed with emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD), four years ago and has been on bronchodilator therapy since then. Deborah has an extensive history of smoking, with an 80-pack-year record, which is a significant risk factor for her condition. Her symptoms have been worsening over the past few days, with her describing her chest soreness as mild pressure, rating it a three on a 1-10 scale.
The pain is more pronounced over the anterior thorax and ribs, which she attributes to severe coughing. She has had a nonproductive cough for the past four days and reports feeling more fatigued than usual. Upon observation, Deborah is seen sitting in a tripod position, a familiar posture in patients with COPD that aids in breathing.
With type 2 diabetes, hypertension, osteoarthritis, and COPD, in addition to three to four exacerbations recorded this year, her prior medical history is essential. Her surgical background includes cholecystectomy and appendectomy. Breast cancer and hypertension are prevalent in the family. She has a smoking history in her social life and smokes with her spouse, who also smokes. She also provides her mother’s primary care, who is old.
An albuterol inhaler, two puffs as needed every 4-6 hours, metformin 1000mg twice daily for diabetes, lisinopril 20mg-HCTZ 12.5mg once daily in the morning for hypertension, and Symbicort 160mcg/4.5mcg/actuation, two puffs twice daily for COPD are all part of Deborah’s current drug regimen. She has a known penicillin allergy.
Her vital signs at presentation are as follows: a temperature of 100.2°F, an oxygen saturation of 90% on room air, a blood pressure of 128/88 mmHg, a heart rate of 93 beats per minute, and a respiratory rate of 28 breaths per minute. These vitals paint a complete picture of Deborah’s present health status and the difficulties in treating her disease, together with her symptoms and medical history.
Management and Outcome
Deborah has to be managed using a thorough, multidisciplinary strategy that takes into account her comorbid conditions, COPD, and lifestyle choices. The primary objectives of COPD therapy are to reduce symptoms, decrease the frequency and severity of exacerbations, enhance health status, and increase exercise tolerance (Alqahtani et al., 2021). Deborah looks to be suffering a COPD exacerbation based on her symptoms, which are perhaps being brought on by a respiratory infection, as seen by her fever and the recent beginning of an ineffective cough. The increased use of bronchodilators and consideration of a brief course of systemic corticosteroids should be part of the initial therapy plan, as they have been found to enhance lung function and reduce the likelihood of early relapse, treatment failure, and the duration of hospital stay (Aisanov & Khaltaev, 2020). Given the potential for a bacterial respiratory infection, antibiotics may also be considered.
Her comorbidities, such as diabetes and hypertension, should still be treated in accordance with recommended practices. It is crucial to monitor her blood sugar levels closely, as systemic corticosteroids may increase them (Fazleen & Wilkinson, 2020). With the help of her current medication and routine monitoring, her hypertension should be controlled. Deborah has to stop smoking since it is the only strategy that has been shown to halt the progression of COPD. Both she and her husband should be aggressively urged to stop smoking and provided with assistance to do so, given their long histories of smoking.
The patient’s physical and mental health should be improved over the long term with the help of dietary and psychological counseling, exercise programs, illness management training, and pulmonary rehabilitation. To lower the risk of respiratory infections, vaccinations such as the pneumococcal vaccine and the yearly influenza vaccine should be administered (Molin et al., 2020; Siltanen et al., 2020). The success of Deborah’s treatment will rely on several variables, including her willingness to comply with treatment, her capacity to stop smoking, and how she reacts to therapy. Appointments should be made for frequent follow-up visits so that her progress can be tracked, her treatment may be changed as needed, and she can continue to get assistance for quitting smoking (Dahne et al., 2022; Anakal, 2022). Deborah can enhance her quality of life and halt the development of her COPD with proper management.
Discussion
In Deborah’s case, a chronic and progressive condition predominantly brought on by repeated exposure to lung irritants, most frequently tobacco smoke, is depicted in a usual way. COPD is a severe illness that can cause early mortality and considerable long-term impairment, not merely a “smoker’s cough” (Watson & Wilkinson, 2022). Damage to the lungs is only one aspect of the illness. It frequently affects persons who have systemic disorders and is made more difficult by associated comorbidities. Due to this, managing COPD is a complex process that requires a thorough, multidisciplinary approach.
Deborah has a substantial risk factor for COPD due to her extensive smoking history. She could also be affected by her husband’s smoking habit, which exposes her to secondhand smoke. Therefore, healthcare professionals should continue to encourage patients and provide them with tools to help them quit (Philibert et al., 2021).
Deborah is an example of a patient with COPD who frequently has numerous comorbidities; this is more common than not. The patient’s quality of life and prognosis for COPD may both be significantly impacted by these comorbidities (Van Bakel et al., 2021). Consequently, a thorough examination of comorbidities should always be part of the care of COPD.
Conclusion
Deborah’s case offers essential insight into the challenges of managing a patient with COPD, a chronic and progressive illness that profoundly affects overall health and quality of life. Her situation highlights the significance of a thorough, multidisciplinary approach to therapy that tackles not just the respiratory symptoms but also the comorbidities and lifestyle factors that hasten the disease. A holistic approach to care is required when multiple comorbidities are present in COPD patients, as was the case in Deborah’s point, to ensure that all facets of the patient’s health are taken into consideration.
Despite the fact that COPD is currently incurable, proper care may significantly enhance a patient’s quality of life, limit the disease’s development, and lower the likelihood of exacerbations. To modify treatment plans as needed and provide patients with continuous support, regular follow-up, and monitoring is essential. Deborah’s story serves as a poignant reminder of the impact COPD has on individuals and the vital role healthcare professionals play in managing this complex condition.
References
Alqahtani, J. S., Alghamdi, S. M., Aldhahir, A. M., Althobiani, M., & Oyelade, T. (2021). Key toolkits of non-pharmacological management in COPD: During and beyond COVID-19. Frontiers in Bioscience, 26(7), 246.
Aisanov, Z., & Khaltaev, N. (2020). Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients. Journal of Thoracic Disease, 12(5), 2791–2802.
Anakal, S. (2022). Decision Support System for Drug-Drug Interaction Pertaining to COPD and its Comorbidities. International Journal of Education and Management Engineering (IJEME).
Dahne, J., Player, M. S., Strange, C., Carpenter, M. J., Ford, D. W., King, K. M., Miller, S., Kruis, R., Hawes, E., Hidalgo, J. E., & Diaz, V. A. (2022). Proactive electronic visits for smoking cessation and chronic obstructive pulmonary disease screening in primary care: A randomized controlled trial of feasibility, acceptability, and efficacy. Journal of Medical Internet Research, 24(8), e38663.
Fazleen, A., & Wilkinson, T. (2020). Early COPD: Current evidence for diagnosis and management. Therapeutic Advances in Respiratory Disease, 14, 175346662094212.
Molin, K. R., Søndergaard, J., Lange, P., Egerod, I., Langberg, H., & Lykkegaard, J. (2020). Danish general practitioners’ management of patients with COPD: A nationwide survey. Scandinavian Journal of Primary Health Care, 38(4), 391–398.
Philibert, R. A., Dawes, K., Philibert, W., Andersen, A. D., & Hoffman, E. A. (2021). Alcohol use intensity decreases in response to successful smoking cessation therapy. Genes, 13(1), 2.
Siltanen, H., Aine, T., Huhtala, H., Kaunonen, M., Vasankari, T., & Paavilainen, E. (2020). Psychosocial issues need more attention in COPD self-management education. Scandinavian Journal of Primary Health Care, 38(1), 47–55.
Van Bakel, S. I. J., Gosker, H. R., Langen, R. C. J., & Schols, A. M. W. J. (2021). Towards personalized management of sarcopenia in COPD. International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, 25–40.
Watson, A., & Wilkinson, T. (2022). Digital healthcare in COPD management: A narrative review on the advantages, pitfalls, and need for further research. Therapeutic Advances in Respiratory Disease, 16.